Physician profile
Ahmet Dogan
NPI 1457408056
$24,544.93
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,877 · 2020: $4,050 · 2022: $2,973 · 2024: $9,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,005 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,200 · Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,005.18 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,200.00 |
| Food and Beverage | $439.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| F. Hoffmann-La Roche Ag | $6,388.93 | 2019-2024 | |
| Eusa Pharma (US) LLC | $6,270.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $4,862.26 | 2024 | |
| Seagen INC. | $4,050.32 | 2020 | |
| Eli Lilly and Company | $1,800.00 | 2022 | |
| Incyte Corporation | $1,173.00 | 2022 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmet Dogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.